Navigation Links
AEterna Zentaris to Report Data from Safety Study of Phase 3 Program in Benign Prostatic Hyperplasia with Cetrorelix Ahead of Schedule
Date:6/15/2009

Merck Serono) in the U.S., Europe and in several other countries, as well as in Japan through Shionogi.

About Benign Prostatic Hyperplasia

Benign prostatic hyperplasia (BPH) is one of the most common diseases of aging men - affecting more than 20 million men in the United States - but its etiology is far from being completely understood. Data from ongoing research suggest BPH and lower urinary tract symptoms (LUTS) are more complex conditions than once thought. While previous research on BPH etiology tended to focus on testosterone and other hormones, more recent research suggests other factors - including inflammation, various growth factors, and adrenoreceptors - actually may play a greater role in the development of BPH and LUTS.

BPH is associated with LUTS, including: frequent urination, a sudden, uncontrollable urge to urinate, waking at night to urinate (nocturia), difficulty starting a urine stream (hesitancy and straining), decreased strength of the urine stream (weak flow), feeling that the bladder is not completely empty, an urge to urinate again soon after urinating and pain during urination (dysuria). Currently available therapies may improve symptoms to some degree, but often come with sexual and other side effects.

About AEterna Zentaris Inc.

AEterna Zentaris Inc. is a global biopharmaceutical company focused on endocrine therapy and oncology, with proven expertise in drug discovery, development and commercialization. News releases and additional information are available at www.aezsinc.com.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which could cause the Company's actual results to
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. AEterna Zentaris Opens Extended Study for Cetrorelix in Benign Prostatic Hyperplasia
2. AEterna Zentaris Discloses Preliminary Phase 2 Trial Results for Perifosine in Combination with Radiotherapy for Non-Small Cell Lung Cancer
3. AEterna Zentaris Acquires All Assets from Ardana for Growth Hormone Secretagogue Compound, AEZS-130
4. AEterna Zentaris Presents Data Supporting Evaluation of AEZS-108 in Prostate Cancer at ASCO Meeting
5. AEterna Zentaris to Present Data Supporting Evaluation of AEZS-108 in Prostate Cancer at Upcoming ASCO Meeting
6. AEterna Zentaris to Announce First Quarter 2009 Financial and Operating Results and Hold Annual Shareholder Meeting on May 6, 2009
7. AEterna Zentaris Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement
8. AEterna Zentaris Presents Phase 1 Results for AEZS-112 in Patients with Advanced Cancer and Lymphoma at AACR Annual Meeting in Denver
9. AEterna Zentaris Presents Two Posters on its PI3K Inhibitor Compound, AEZS-126, at AACR Annual Meeting
10. AEterna Zentaris To Present Data on Anticancer Compounds AEZS-112 and AEZS-126 at AACR Annual Meeting
11. AEterna Zentaris Reports Fourth Quarter and Full-Year 2008 Financial and Operating Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/12/2014)... Albany, New York (PRWEB) July 12, 2014 ... market analysis for various reagents used in ... biotechnology is driving the life science reagents ... this study include manufacturers and providers of ... Science Reagents Market Report: http://www.transparencymarketresearch.com/life-sciences-reagents-analytical-reagents.html . ...
(Date:7/11/2014)... , July 11, 2014 , Not ... in, into or from any jurisdiction where to do so ... jurisdiction.  Shire plc ("Shire" or the "Company") (LSE: ... this afternoon.  Shire confirms it has held a meeting with ... by Shire without the prior agreement or approval of AbbVie. ...
(Date:7/11/2014)... 11, 2014 BCC Research ( http://www.bccresearch.com ... POLYMERASE CHAIN REACTION (PCR) TECHNOLOGY: GLOBAL MARKETS , the ... reached nearly $140 billion in 2013. This is estimated ... five-year compound annual growth rate (CAGR) of 28.6%. , ... interesting and exciting possibilities within the broader PCR field. ...
(Date:7/11/2014)... - Sunovion Pharmaceuticals Canada Inc. (Sunovion) today announced that ... use as a once-daily adjunctive therapy for the treatment ... not satisfactorily controlled with conventional therapy.  APTIOM TM ... years of age. Epilepsy is one ... Epilepsy Canada, it affects 0.6% of the population and ...
Breaking Biology Technology:Transparency Market Research: Life Science Reagents Market- PCR Reagent Kits, Cell and Tissue Culture, Flow Cytometry, Electrophoresis and Chromatography 2Transparency Market Research: Life Science Reagents Market- PCR Reagent Kits, Cell and Tissue Culture, Flow Cytometry, Electrophoresis and Chromatography 3Shire plc - Statement re: Media Speculation 2Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 2Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4
... , PITTSBURGH , Jan. 28 ... Carnegie Science Awards, sponsored by Eaton Corporation. , Carnegie ... to recognize and promote outstanding science and technology achievements in ... the Carnegie Science Awards have honored the accomplishments of more ...
... AbsoluteProof ... ... 28, 2010 -- Surety, LLC , the leading provider of data integrity ... selected Surety,s AbsoluteProof® trusted, digital timestamping service for integration into its lab informatics systems ...
... , , , ... Pharmaceutical group,AstraZeneca announced it,s Q4 and full-year results today with CEO ... that cost,control and restructuring had helped deliver a revenue line ... Brennan looks at the results and the drivers behind a 23%,rise ...
Cached Biology Technology:2010 Carnegie Science Awardees Announced 22010 Carnegie Science Awardees Announced 32010 Carnegie Science Awardees Announced 42010 Carnegie Science Awardees Announced 52010 Carnegie Science Awardees Announced 6Biotech Company Ansaris Selects Surety for Integrity and Authenticity Protection of Its Lab Informatics Data 2Biotech Company Ansaris Selects Surety for Integrity and Authenticity Protection of Its Lab Informatics Data 3Biotech Company Ansaris Selects Surety for Integrity and Authenticity Protection of Its Lab Informatics Data 4AstraZeneca CEO Interviewed on Q4 and Full-Year Results 2009 2
(Date:7/11/2014)... There were many fires burning in eastern New South ... July 11. , At 03:35 UTC on July 11 ... when Aqua passed over eastern New South Wales (NSW), ... natural-color visible image of the region and spotted smoke ... by MODIS,s thermal bands, are outlined in red. , ...
(Date:7/11/2014)... news release is available in German . ... is a method that uses the refraction of X-rays ... The images produced with this method are often of ... scientists in the team of Prof. Franz Pfeiffer are ... imaging and therapy including X-ray phase-contrast imaging. One ...
(Date:7/11/2014)... Researchers from Salk Institute for Biological Studies, BGI, ... the safety and reliability of the existing targeted ... method, TALEN-HDAdV, which could significantly increased gene-correction efficiency ... study published online in Cell Stell Cell ... cell-based gene therapy. , The combination of stem ...
Breaking Biology News(10 mins):New simple setup for X-ray phase contrast 2A new genome editing method brings the possibility of gene therapies closer to reality 2
... of a fungal mold, was discovered in 1929, scientists have ... 20 in the Journal of Chemistry and Biology, a team ... new method that may speed the ongoing quest for medically ... single fungal protein, the team, led by professor of plant ...
... New evidence is emerging that climate change could reduce ... also international efforts to cut poverty. However, the recent ... with some of the tools they need to help ... of the problem. , The new knowledge generated by ...
... have been the warmest year in a century, according to ... Climatologists at NASA's Goddard Institute for Space Studies (GISS) in ... surface temperature in more than a century was recorded in ... research groups that study climate change rank 2005 as the ...
Cached Biology News:Mining for gems in the fungal genome 2Mining for gems in the fungal genome 3Climate change: The rice genome to the rescue 2Climate change: The rice genome to the rescue 32005 was the warmest year in a century 2
...
Mouse polyclonal antibody to PRDM2 - PR domain containing 2, with ZNF domain...
Anti Human S14G-Humanin Polyclonal Antibody...
... LABTrack provides a familiar interface for ... and warehousing. The transition from paper ... transparent. LABTrack contains an integrated ... and rules mechanism. These functions allow ...
Biology Products: